SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (12093)6/13/2013 4:10:06 PM
From: NTTG1 Recommendation

Recommended By
Pogeu Mahone

  Respond to of 13111
 
Most of the delays are the result of poor planning at PVCT and over interpretation of their data. Everyone knew in 2010 that PVCT would have to do work on MOA, most companies are well into these studies by the end of PII clinical trials, not PVCT.

Lots of drugs moved forward during the 'FDA change" of 2011, PVCT is stalled even into 2013...two years later????? If others make progress with the FDA but PVCT does not, how can the problem be with the FDA????? Maybe PVCT (or their proponents, pumpers) mis-interpreted or mis-represented the "AA" signal, :-)

Evidence is clear that experienced companies knew what they were doing and moved forward, PVCT did not. The market is flooded with the products of their work, not RB...simple stuff



To: Mimbari who wrote (12093)6/13/2013 10:17:51 PM
From: dirkdiggler  Read Replies (3) | Respond to of 13111
 
If in fact they do some type of designation from the FDA, the listing of the on Nasq probably won't matter except internal company politics of the acquiring company ie. Easier for the board the give approval for purchase.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News